Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurosearch

Executive Summary

Cell and gene therapy program will be spun off as NsGene, CEO Jorgen Buus Lassen announced Sept. 30 at the Warburg Dillon Read Global Life Sciences Conference. Researchers, partners and collaborative agreements will all be shifted to NsGene. The group is considering therapies for Parkinson's disease, including a neublastin secreting cell line for protective therapy, and restorative therapy with dopaminergic neuronal precursor cell lines. "We expect that within three years, we can be in clinical studies within those new cell lines," Lassen said. Neurosearch aims to have financing for the spin off complete by the end of the year
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS034977

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel